WuXi AppTec broadens its capabilities in peptide and API manufacturing
The expansion will increase the total reactor volume of solid-phase
WuXi AppTec recently shared exciting news about its plans to expand its manufacturing facilities. The company will be adding two new peptide manufacturing plants, one at its Changzhou facility and another at its Taixing site in China. This expansion is a significant step forward for WuXi AppTec. The expansion will increase the total reactor volume of solid-phase peptide synthesis to 32,000 L. The plants will utilize digital operating systems with automated solvent delivery to optimize production and minimize human errors, resulting in a reduction in production cycle time.
The recently constructed peptide plant in Taixing covers a vast expanse of 169 acres and is designed to support the production of various synthetic molecules, such as small molecules, peptides, oligonucleotides, and conjugates. The first phase of construction, scheduled to be operational in 2025, will consist of nine plants with a combined reactor volume exceeding 1000 m3. A specialized plant will be included to accommodate API cleanrooms. Upon completion, the expansion will significantly boost WuXi AppTec's total reactor volume for small-molecule API and intermediate manufacturing to over 4000 m3.
The launch of our new peptide manufacturing plants and the development of the new Taixing site mark significant achievements for WuXi AppTec. Our increased capacity is crucial for speeding up drug development and guaranteeing a dependable supply chain for our partners worldwide. Minzhang Chen, co-CEO of WuXi AppTec, emphasized the company's commitment to improving their capability and capacity, with a focus on delivering innovative therapies to patients worldwide, according to a press release.
WuXi AppTec's TIDES CRDMO platform offers a range of services for API and drug product development, covering everything from discovery to commercial stages. They specialize in working with oligonucleotides, peptides, and conjugates. In 2023, the company provided support for around 50 peptide projects, ranging from preclinical to commercial stages-peptide synthesis to 32,000 L.
Source: WuXi AppTec
